Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleNEUROPHARMACOLOGY

Benzodiazepine Binding Site Occupancy by the Novel GABAA Receptor Subtype-Selective Drug 7-(1,1-Dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine (TPA023) in Rats, Primates, and Humans

John R. Atack, Dean F. Wong, Tim D. Fryer, Christine Ryan, Sandra Sanabria, Yun Zhou, Robert F. Dannals, Wai-si Eng, Raymond E. Gibson, H. Donald Burns, Jose M. Vega, Laura Vessy, Paul Scott-Stevens, John S. Beech, Jean-Claude Baron, Bindi Sohal, Michael L. Schrag, Franklin I. Aigbirhio, Ruth M. McKernan and Richard J. Hargreaves
Journal of Pharmacology and Experimental Therapeutics January 2010, 332 (1) 17-25; DOI: https://doi.org/10.1124/jpet.109.157909
John R. Atack
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dean F. Wong
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tim D. Fryer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christine Ryan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sandra Sanabria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yun Zhou
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert F. Dannals
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wai-si Eng
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Raymond E. Gibson
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
H. Donald Burns
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jose M. Vega
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laura Vessy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul Scott-Stevens
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John S. Beech
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jean-Claude Baron
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bindi Sohal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael L. Schrag
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Franklin I. Aigbirhio
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ruth M. McKernan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard J. Hargreaves
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

The GABAA receptor α2/α3 subtype-selective compound 7-(1,1-dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine (TPA023; also known as MK-0777) is a triazolopyridazine that has similar, subnanomolar affinity for the benzodiazepine binding site of α1-, α2-, α3-, and α5-containing GABAA receptors and has partial agonist efficacy at the α2 and α3 but not the α1 or α5 subtypes. The purpose of the present study was to define the relationship between plasma TPA023 concentrations and benzodiazepine binding site occupancy across species measured using various methods. Thus, occupancy was measured using either in vivo [3H]flumazenil binding or [11C]flumazenil small-animal positron emission tomography (microPET) in rats, [123I]iomazenil γ-scintigraphy in rhesus monkeys, and [11C]flumazenil PET in baboons and humans. For each study, plasma-occupancy curves were derived, and the plasma concentration of TPA023 required to produce 50% occupancy (EC50) was calculated. The EC50 values for rats, rhesus monkeys, and baboons were all similar and ranged from 19 to 30 ng/ml, although in humans, the EC50 was slightly lower at 9 ng/ml. In humans, a single 2-mg dose of TPA023 produced in the region of 50 to 60% occupancy in the absence of overt sedative-like effects. Considering that nonselective full agonists are associated with sedation at occupancies of less than 30%, these data emphasize the relatively nonsedating nature of TPA023.

Footnotes

  • ↵1 Current affiliation: Johnson & Johnson Pharmaceutical Research and Development, Beerse, Belgium.

  • ↵2 Current affiliation: Amgen, Inc., Thousand Oaks, California.

  • ↵3 Current affiliation: GlaxoSmithKline, Stevenage, United Kingdom.

  • ↵4 Current affiliation: Novartis, Horsham, Surrey, United Kingdom.

  • ↵5 Current affiliation: Pfizer Global Research and Development, Sandwich, Kent, United Kingdom.

  • This work was funded by Merck.

  • Article, publication date, and citation information can be found at http://jpet.aspetjournals.org.

    doi:10.1124/jpet.109.157909

  • ABBREVIATIONS:

    L-838417
    7-(1,1-dimethylethyl)-6-(2-methyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2,5-difluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine
    TPA023 (also known at MK-0777)
    7-(1,1-dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine
    Occ50
    dose corresponding to 50% occupancy
    PET
    positron emission tomography
    Ro 15-1788
    8-fluoro-5,6-dihydro-5-methyl-6-oxo-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylic acid ethyl ester
    PEG
    polyethylene glycol
    EtOH
    ethanol
    MRK-409 (also know as MK-0343)
    7-cyclobutyl-6-(2-methyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2,6-difluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine
    TPA023B
    6,2′-difluoro-5′-[3-(1-hydroxyl-1-methylethyl)imidazo[1,2-b][1,2,4]triazin-7-yl]biphenyl-2-carbonitrile
    SL65.1498
    6-fluoro-9-methyl-2-phenyl-4-(pyrrolidin-1-yl-carbonyl)-2,9-dihydro-1-H-pyrido[3,4-b]indol-1-one
    α51A
    α5 subtype-selective triazolopthalazine 3-(5-methylisoxazol-3-yl)-6-[(1-methyl-1,2,3-triazol-4-yl)methyloxy-1,2,4-triazolo[3,4-α]phthalazine.

    • Received June 18, 2009.
    • Accepted August 27, 2009.
  • © 2010 by The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 332 (1)
Journal of Pharmacology and Experimental Therapeutics
Vol. 332, Issue 1
1 Jan 2010
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Benzodiazepine Binding Site Occupancy by the Novel GABAA Receptor Subtype-Selective Drug 7-(1,1-Dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine (TPA023) in Rats, Primates, and Humans
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleNEUROPHARMACOLOGY

Benzodiazepine Binding Site Occupancy by the Novel GABAA Receptor Subtype-Selective Drug 7-(1,1-Dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine (TPA023) in Rats, Primates, and Humans

John R. Atack, Dean F. Wong, Tim D. Fryer, Christine Ryan, Sandra Sanabria, Yun Zhou, Robert F. Dannals, Wai-si Eng, Raymond E. Gibson, H. Donald Burns, Jose M. Vega, Laura Vessy, Paul Scott-Stevens, John S. Beech, Jean-Claude Baron, Bindi Sohal, Michael L. Schrag, Franklin I. Aigbirhio, Ruth M. McKernan and Richard J. Hargreaves
Journal of Pharmacology and Experimental Therapeutics January 1, 2010, 332 (1) 17-25; DOI: https://doi.org/10.1124/jpet.109.157909

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleNEUROPHARMACOLOGY

Benzodiazepine Binding Site Occupancy by the Novel GABAA Receptor Subtype-Selective Drug 7-(1,1-Dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine (TPA023) in Rats, Primates, and Humans

John R. Atack, Dean F. Wong, Tim D. Fryer, Christine Ryan, Sandra Sanabria, Yun Zhou, Robert F. Dannals, Wai-si Eng, Raymond E. Gibson, H. Donald Burns, Jose M. Vega, Laura Vessy, Paul Scott-Stevens, John S. Beech, Jean-Claude Baron, Bindi Sohal, Michael L. Schrag, Franklin I. Aigbirhio, Ruth M. McKernan and Richard J. Hargreaves
Journal of Pharmacology and Experimental Therapeutics January 1, 2010, 332 (1) 17-25; DOI: https://doi.org/10.1124/jpet.109.157909
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Combination therapy against cholinergic-induced SE
  • Sex Differences in Benzodiazepine Refractory Status Epilepticus
  • Biodistribution of Agmatine to Brain and Spinal Cord
Show more Neuropharmacology

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics